NEKTAR THERAPEUTICS

Nektar Therapeutics is a biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders and inflammatory conditions. The company's primary development programs include NKTR-358, a regulatory T cell stimulator intended to address immune imbalances in autoimmune and chronic inflammatory diseases, and PEG-CSF1, a modified colony stimulating factor designed to modulate inflammation resolution across multiple therapeutic indications. Additional programs include a TNF receptor type II agonist antibody and NKTR-255, an IL-15 receptor agonist for cancer immunotherapy.

Nektar maintains an extensive partnership network with major pharmaceutical companies, including Takeda, AstraZeneca, Roche, Pfizer, Bristol-Myers Squibb, and Merck KGaA. These collaborations span development, commercialization, and licensing arrangements across its pipeline programs. The company is incorporated in Delaware and headquartered in San Francisco, California, with 61 full-time employees as of the most recent reporting period. As a development-stage biopharmaceutical company, Nektar operates internationally with a business model dependent on advancing its clinical-stage programs toward regulatory approval and generating potential revenue through partner royalties and milestone payments.